Sign up for our newsletter
All-time Popular Posts
A biobetter trastuzumab is on the way
World’s first biosimilar antibody* is approved in Korea
A biosimilar manufacturer: Celltrion
Biosimilar Remicade under review in EU
Boehringer starts with adalimumab biosimilar
Celltrion’s first biosimilar antibody is about to reach the market
Biosimilars in Emerging Markets
Indian Biosimilars Market
Tags
Amgen BPCIA Celltrion Conference Congress EMA Enbrel Epoetin EU FDA G-CSF Genentech Guideline Herceptin Immunogenicity India Interchangeability Japan London Mabthera Merck Monoclonal Antibodies Rituxan rituximab Roche Sandoz South Korea Teva Training trastuzumab UK USAArchives
Events Calendar
M | T | W | T | F | S | S |
---|---|---|---|---|---|---|
28 | 29 | 30 | 31 | 1 | 2 | 3 |
4 February 4, 2013x | 5 February 5, 2013x | 6 | 7 February 7, 2013x | 8 February 8, 2013x | 9 | 10 |
11 | 12 | 13 | 14 | 15 | 16 | 17 |
18 | 19 February 19, 2013x | 20 February 20, 2013x | 21 | 22 | 23 | 24 |
25 | 26 February 26, 2013x | 27 February 27, 2013x | 28 February 28, 2013x | 1 March 1, 2013x | 2 | 3 |
Post Tagged with: "ulcerative colitis"
Recent posts
- Biotech firms are trying to limit biosimilars in the US
- Amgen backs states’ efforts to enact biosimilar legislation that allows for substitution and supports patient safety
- The Biosimilars Game: A market research report from BioWorld
- Synthon reports positive early results with its second generation HER2-antibody-drug conjugate
- Biosimilars to replace 70% of chemical drugs in 2 decades
Recent Comments
- Ron Rader on Biosimilars to replace 70% of chemical drugs in 2 decades
- Mario on Biosimilars analytical characterization and comparability studies seminar
- Dr Mohamed Fathi SAFFAR on Iran making advancements in biosimilar medicines
- Andrea M on Pfizer starts biosimilar rituximab Phase I/II trial
- Rahulsingh Thakur on Biosimilars approved in Europe
Share an Article?
Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.
We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?
Suggestions?
Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!